Advancing oncological practice with innovative cancer data analytics: A new exponential-generated class of distributions.

Traditional predictive modeling techniques have significantly influenced the analysis of survival times and predictive markers in oncology. However, these models often do not fully address the complexities of cancer data, leading to a noticeable gap in accurately modeling both cancer survival and mortality. The aim of this study is to show a model that offers the best fit for cancer mortality and survival data, thereby improving treatment strategies and patient prognoses. I propose the a New Exponential-Weibull (NEWE) distribution within the New Exponential-Generated (NE-G) class of distributions to enhance oncological analytics with greater accuracy and comprehensiveness. An empirical analysis of Brazilian cancer mortality data is conducted., This data set covers children, head and neck, and cervical cancer. Concurrently, survival time-to-event data for bladder and advanced lung cancers patients are assessed to evaluate the model's effectiveness. Based on standard metrics, extensive simulation experiments show the Maximum Product of Spacing Estimator as the best of seven-point estimation techniques. The NEWE distribution shows superior modeling capabilities, surpassing traditional models with lower values of Log-likelihood, Cramer-von Mises, and Anderson-Darling and higher Kolmogorov-Smirnov (KS) p-values. The study also discerns the most fitting estimators for distinct types of cancer mortality and survival data. This includes the Right Tail Anderson-Darling for child cancer deaths, the Maximum Product Spacing for head and neck cancer deaths, the Least Squares for cervical cancer deaths, the Weighted Least Squares for bladder cancer survival, and the Anderson-Darling for advanced lung cancer deaths. This shows that the NEWE distribution can be used in a number of different cancers settings. The development and implementation of the NEWE distribution marks a significant advancement in oncological modeling. By analyzing both cancer mortality and survival data with enhanced accuracy and flexibility, this novel approach surpasses traditional models, offering deeper insights into cancer progression and treatment outcomes. As a result, the NEWE distribution equips healthcare professionals with a powerful tool for improving clinical decisions, leading to better prognostic assessments and patient care in cancer treatment. [ABSTRACT FROM AUTHOR]